Blogs (8)

Tirabrutinib is a Selective BTK Inhibitor

Tirabrutinib is a selective and novel inhibitor of BTK, Tirabrutinib prevents B-cell receptor signaling and impeding B-cell development.
Flavopiridol (Alvocidib) is a pan CDK Inhibitor

Flavopiridol is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
Ruxolitinib (INCB018424) is an Orally Active JAK1 and JAK2 Inhibitor

Ruxolitinib is a potent and selective JAK1/2 inhibitor and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy.
GSK143 is an Orally Active and Highly Selective Spleen Tyrosine Kinase (SYK) Inhibitor

GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
WZ811 is an Orally Active CXCR4 Antagonist

WZ811 is an orally active, highly potent competitive antagonist of CXCR4, which inhibits chronic lymphocytic leukemia progression and tumorigenesis.
NXT629 is a Selective and Competitive PPARα Antagonist

NXT629 is a potent, selective, and competitive PPAR-α antagonist and shows high selectivity over other nuclear hormone receptor.
TAK-659 is a Dual SYK and FLT-3 Kinase Inhibitor for Leukemia Treatment

TAK-659 is a highly potent, selective, reversible and orally available inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3).
MT-802 is a PROTAC Degrader of BTK for C481S Mutant CLL Treatment

MT-802 is a potent BTK degrader based on PROTAC technology, with a DC50 of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia.

Name
Email *

	Sorry, but the email address you supplied was invalid.